Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 HKD | -0.88% | -9.60% | -22.60% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.60% | 148M | |
+0.99% | 91.72B | |
0.00% | 39.44B | |
-10.35% | 34.47B | |
+64.64% | 26.7B | |
-16.15% | 15.13B | |
-6.98% | 13.27B | |
-11.77% | 11.74B | |
-49.19% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. Appoints Zhengqing Li as Chief Medical Officer and President of R&D Greater China